Combined Low Dose Rate Brachytherapy and External Beam Radiation Therapy for Intermediate-Risk Prostate Cancer.

This is a retrospective study conducted to report the tumor control and late toxicity outcomes of patients with intermediate-risk prostate cancer undergoing combination external beam radiation therapy and low dose rate brachytherapy (LDR-PB).

Thirty-one patients received 45 Gray (Gy) of external beam radiation therapy to the prostate and seminal vesicles, together with a brachytherapy boost via a transperineal prostate implant of I125 (108 Gy). In addition, some patients received 6 months of androgen deprivation therapy depending on physician preference. Biochemical failure was defined using the Phoenix consensus definition of the nadir PSA +2 ng/mL. Toxicity was graded using the Common Terminology Criteria for Adverse Events version 4.0.

The biochemical progression-free survival, metastases-free survival, and overall survival at 5 years were 87.1%, 96.3%, and 92%, respectively. The incidence of late grade ≥1 and ≥2 genitourinary (GU) toxicities were 54.8% and 6.5%, respectively. The incidence of late grade 3 GU toxicity was 6.5% with urinary retention occurring in two patients requiring either a bladder neck incision or transurethral resection of the prostate. The incidence of late grade ≥1 and 2 gastrointestinal toxicities were 19.4% and 6.5%, respectively. No patients developed grade 3 gastrointestinal toxicity.

Our small series has shown a high biochemical progression-free survival consistent with the ASCENDE-RT and NRG Oncology/RTOG0232 LDR-PB boost arms. In addition, the risk of late grade 3 GU toxicity is far lower than that reported by the ASCENDE-RT study but comparable to other LDR-PB boost and LDR alone reports in the literature. Therefore, we are comfortable to continue offering LDR-PB boost to our patients with intermediate-risk prostate cancer.

Journal of medical imaging and radiation sciences. 2018 Nov 08 [Epub]

Michael Chao, Daryl Lim Joon, Vincent Khoo, Sandra Spencer, Huong Ho, Mario Guerrieri, Farshad Foroudi, Damien Bolton

Genesis Cancer Care Victoria, Ringwood, Australia; The Austin Hospital, Heidelberg, Australia; Ringwood Private Hospital, Ringwood East, Australia; University of Melbourne, Melbourne, Australia. Electronic address: ., The Austin Hospital, Heidelberg, Australia; University of Melbourne, Melbourne, Australia., The Austin Hospital, Heidelberg, Australia; University of Melbourne, Melbourne, Australia; Royal Marsden Hospital, London, UK., Genesis Cancer Care Victoria, Ringwood, Australia., Genesis Cancer Care Victoria, Ringwood, Australia; Ringwood Private Hospital, Ringwood East, Australia., The Austin Hospital, Heidelberg, Australia; Ringwood Private Hospital, Ringwood East, Australia; University of Melbourne, Melbourne, Australia.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe